NEONC TECHNOLOGIES HOLDINGS Business Summary

NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company specializing in the development of proprietary therapeutic platforms for central nervous system (CNS) cancers. The company’s business model centers on the clinical advancement of its lead candidates, NEO100 (purified perillyl alcohol) and NEO212, which utilize a patented intranasal delivery system to bypass the blood-brain barrier—a platform protected by over 179 worldwide patents. Revenue is currently generated through strategic research partnerships, federal grants, and milestone-based licensing, with the company’s primary value proposition tied to its ongoing Phase 2a/2b trials for recurrent glioblastoma and other malignant gliomas. NeOnc competes in the specialized neuro-oncology segment against firms such as Novocure, Northwest Biotherapeutics, and Kazia Therapeutics, distinguishing itself through a non-invasive, patient-administered delivery method designed to improve therapeutic efficacy and patient compliance compared to traditional systemic or device-based interventions. Founded by Dr. Thomas Chen, a prominent neurosurgeon at the Keck School of Medicine of USC, NeOnc is led by CEO and Executive Chairman Amir F. Heshmatpour, who assumed the chief executive role in November 2025 to spearhead commercialization and global capital strategy. Dr. Chen continues to lead the company’s scientific vision as Chief Medical Officer and Chief Scientific Officer, supported by Chief Clinical Officer Dr. Josh Neman and a board of directors that includes distinguished neurosurgeons Dr. Steven L. Giannotta and Dr. Alan Chiang. The company’s financial position was significantly bolstered in early 2026 by a $10 million PIPE investment from Cinctive Capital Management and a $50 million strategic partnership with Quazar Investment. These resources support the expansion of the "NEO" platform and the development of its UAE-based subsidiary, NuroMENA, established under the chairmanship of Sheikh Nahyan bin Zayed Al Nahyan to facilitate international clinical research.